☆ 4.7 Article

Minimal residual disease quantification in ovarian tissue collected from patients in complete remission of acute leukemia

BLOOD (2021)

Journal

BLOOD

Volume 137, Issue 12, Pages 1697-1701

Publisher

AMER SOC HEMATOLOGY

DOI: 10.1182/blood.2020007782

Keywords

-

Categories

Hematology

Funding

Association Laurette Fugain

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Immunology

Chimeric Antigens Receptor T Cell Therapy Improve the Prognosis of Pediatric Acute Lymphoblastic Leukemia With Persistent/Recurrent Minimal Residual Disease in First Complete Remission

Guan-hua Hu, Yi-fei Cheng, Ying-xi Zuo, Ying-jun Chang, Pan Suo, Jun Wu, Yue-ping Jia, Ai-dong Lu, Ying-chun Li, Yu Wang, Shun-chang Jiao, Long-ji Zhang, Xiang-yu Zhao, Chen-hua Yan, Lan-ping Xu, Xiao-hui Zhang, Kai-yan Liu, Le-ping Zhang, Xiao-jun Huang

Summary: This study demonstrates that CAR-T therapy can effectively eliminate MRD and improve survival in patients with suboptimal MRD response.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Oncology

UMAP Based Anomaly Detection for Minimal Residual Disease Quantification within Acute Myeloid Leukemia

Lisa Weijler, Florian Kowarsch, Matthias Woedlinger, Michael Reiter, Margarita Maurer-Granofszky, Angela Schumich, Michael N. Dworzak

Summary: Acute myeloid leukemia (AML) is the second most common and aggressive type of leukemia in children and adolescents. Flow cytometry is an effective method to monitor the number of remaining leukemic cells in the bone marrow of AML patients, but the data patterns are complex and difficult to identify. An automatic assessment approach using a semi-supervised machine learning model has been developed to address these challenges.

CANCERS (2022)

Add to Collection

Article Oncology

Value of pre-transplant consolidation chemotherapy in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation without minimal residual disease in first complete remission

Weijia Fu, Aijie Huang, Guihua Lu, Xiong Ni, Lei Gao, Li Chen, Jie Chen, Weiping Zhang, Jianmin Yang

Summary: In adult ALL patients with CR1/MRD-negative status, pre-transplant consolidation chemotherapy did not significantly impact survival rates, relapse rates, or non-relapse mortality, while high cytogenetic risk independently predicted poor outcomes.

LEUKEMIA & LYMPHOMA (2021)

Add to Collection

Review Oncology

Molecular Minimal Residual Disease Detection in Acute Myeloid Leukemia

Christian M. Vonk, Adil S. A. Al Hinai, Diana Hanekamp, Peter J. M. Valk

Summary: Although most AML patients achieve CR after initial induction chemotherapy, residual leukemic cells may lead to relapse, with MRD serving as a prognostic marker. Molecular techniques like NGS offer a sensitive assessment of MRD markers, but face challenges such as limited sensitivity/specificity and difficulty in distinguishing mutations. Multiple studies have explored the association between MRD detection by molecular assays and AML relapse, highlighting limitations, challenges, and opportunities.

CANCERS (2021)

Add to Collection

Article Medicine, General & Internal

Haploidentical hematopoietic stem cell transplantation may improve long-term survival for children with high-risk T-cell acute lymphoblastic leukemia in first complete remission

Yongzhan Zhang, Lu Bai, Yifei Cheng, Aidong Lu, Yu Wang, Jun Wu, Xiaohui Zhang, Yingxi Zuo, Lanping Xu, Yueping Jia, Xiaojun Huang, Leping Zhang

Summary: This study found that allo-HSCT, especially haplo-HSCT, can improve survival and reduce relapse in high-risk T-ALL children. Minimal residual disease re-emergence, age, and high white blood cell count are independent risk factors that affect prognosis.

CHINESE MEDICAL JOURNAL (2022)

Add to Collection

Review Oncology

Minimal Residual Disease in Acute Lymphoblastic Leukemia: Current Practice and Future Directions

Gloria Paz Contreras Yametti, Talia H. Ostrow, Sylwia Jasinski, Elizabeth A. Raetz, William L. Carroll, Nikki A. Evensen

Summary: Acute lymphoblastic leukemia minimal residual disease (MRD) is residual leukemia cells present after achieving complete remission, with significant impact on prognosis. Rapid reduction of MRD indicates leukemia sensitivity to therapy, aiding in risk stratification and treatment adjustment.

CANCERS (2021)

Add to Collection

Review Oncology

Acute Myeloid Leukemia Stem Cells in Minimal/Measurable Residual Disease Detection

Kritika Srinivasan Rajsri, Nainita Roy, Sohini Chakraborty

Summary: Acute myeloid leukemia (AML) is a blood cancer characterized by immature blood cells called leukemic blasts. Leukemia stem cells (LSCs) are resistant to chemotherapy and can cause disease relapse. Understanding the molecular basis of LSCs is important in identifying and targeting these cells for more effective treatment.

CANCERS (2023)

Add to Collection

Article Oncology

Clinical Implications of Minimal Residual Disease Detection in Infants With KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol

Janine Stutterheim, Inge M. van der Sluis, Paola de Lorenzo, Julia Alten, Philip Ancliffe, Andishe Attarbaschi, Benoit Brethon, Andrea Biondi, Myriam Campbell, Giovanni Cazzaniga, Gabriele Escherich, Alina Ferster, Rishi S. Kotecha, Birgitte Lausen, Chi Kong Li, Luca Lo Nigro, Franco Locatelli, Rolf Marschalek, Claus Meyer, Martin Schrappe, Jan Stary, Ajay Vora, Jan Zuna, Vincent H. J. van der Velden, Tomasz Szczepanski, Maria Grazia Valsecchi, Rob Pieters

Summary: MRD levels are predictive of outcomes in infant acute lymphoblastic leukemia, helping to guide treatment interventions.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Reproductive Biology

Minimal residual disease detection by multicolor flow cytometry in cryopreserved ovarian tissue from leukemia patients

Tristan Zver, Sophie Frontczak, Catherine Poirot, Aurelie Rives-Feraille, Brigitte Leroy-Martin, Isabelle Koscinski, Francine Arbez-Gindre, Francine Garnache-Ottou, Christophe Roux, Clotilde Amiot

Summary: This study is the first to use MFC to detect MRD in ovarian cortical tissue from leukemia patients. The results demonstrate that MFC is a reliable method to control oncological risk before ovarian tissue transplantation in leukemia patients.

JOURNAL OF OVARIAN RESEARCH (2022)

Add to Collection

Article Oncology

Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial

Alexander Schmitz, Rasmus Froberg Brondum, Hans Erik Johnsen, Ulf-Henrik Mellqvist, Anders Waage, Peter Gimsing, Davine Hofste Op Bruinink, Vincent van der Velden, Bronno van der Holt, Markus Hansson, Niels Frost Andersen, Ulf Christian Frolund, Carsten Helleberg, Fredrik H. Schjesvold, Lucia Ahlberg, Nina Gulbrandsen, Bjorn Andreasson, Birgitta Lauri, Einar Haukas, Julie Stove Bodker, Anne Stidsholt Roug, Martin Bogsted, Marianne T. Severinsen, Henrik Gregersen, Niels Abildgaard, Pieter Sonneveld, Karen Dybkaer

Summary: This study demonstrates that longitudinal monitoring of minimal residual disease using flow cytometry can predict disease progression earlier and with higher sensitivity in multiple myeloma patients. Increasing levels of minimal residual disease in the bone marrow precede biochemically assessed changes and indicate subsequent clinical progression.

BMC CANCER (2022)

Add to Collection

Review Medicine, General & Internal

The Role of Wilms' Tumor Gene (WT1) Expression as a Marker of Minimal Residual Disease in Acute Myeloid Leukemia

Davide Lazzarotto, Anna Candoni

Summary: Monitoring Minimal Residual Disease (MRD) is crucial in acute myeloid leukemia (AML) for guiding treatment, determining the need for stem cell transplantation, and detecting relapse early. However, more than 50% of AML patients lack specific molecular markers for MRD monitoring. This review focuses on the use of WT1 overexpression as an MRD marker in AML patients undergoing intensive chemotherapy, including stem cell transplantation. The standardized method of European LeukemiaNet is recommended for achieving optimal sensitivity and specificity.

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Article Oncology

Combination of KIT and FLT3-ITD mutation status with minimal residual disease levels guides treatment strategy for adult patients with inv(16) acute myeloid leukemia in first complete remission

Jun Wang, Feng-Ting Dao, Yu Wang, Hao Jiang, Lan-Ping Xu, Xiao-Su Zhao, Xiao-Hui Zhang, Kai-Yan Liu, Xiao-Jun Huang, Qian Jiang, Ya-Zhen Qin

Summary: This study investigated the benefits of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for inv(16) acute myeloid leukemia (AML) patients in first complete remission (CR1) based on the combination of mutation status and minimal residual disease (MRD) levels. The results showed that allo-HSCT significantly improved both the cumulative incidence of relapse (CIR) and overall survival (OS) for high-risk patients, had a favorable effect on CIR for intermediate-risk patients, and had no significant effect on CIR and OS for low-risk patients.

HEMATOLOGICAL ONCOLOGY (2022)

Add to Collection

Article Immunology

Comparable outcomes in patients with B-cell acute lymphoblastic leukemia receiving haploidentical hematopoietic stem cell transplantation: Pretransplant minimal residual disease-negative complete remission following chimeric antigen receptor T-cell therapy versus chemotherapy

Ting-Ting Yang, Ye Meng, De-Lin Kong, Guo-Qing Wei, Ming-Ming Zhang, Wen-Jun Wu, Ji-Min Shi, Yi Luo, Yan-Min Zhao, Jian Yu, Rui-Rui Jing, Meng-Yu Zhao, Hou-Li Zhao, He Huang, Yong-Xian Hu

Summary: CAR-T therapy followed by haplo-HSCT achieves comparable outcomes to chemotherapy-based MRD-negative CR1 in patients with R/R B-ALL, without increased risk of transplant-related mortality and toxicity.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Oncology

Clinical impact of minimal residual disease and genetic subtypes on the prognosis of childhood acute lymphoblastic leukemia

Chih-Hsiang Yu, Shiann-Tarng Jou, Ying-Hui Su, Elane Coustan-Smith, Gang Wu, Chao-Neng Cheng, Meng-Yao Lu, Kai-Hsin Lin, Kang-Hsi Wu, Shu-Huey Chen, Fang-Liang Huang, Hsiu-Hao Chang, Jinn-Li Wang, Hsiu-Ju Yen, Meng-Ju Li, Shu-Wei Chou, Wan-Ling Ho, Yen-Lin Liu, Chia-Ching Chang, Ze-Shiang Lin, Chien-Yu Lin, Hsuan-Yu Chen, Yu-Ling Ni, Dong-Tsamn Lin, Shu-Wha Lin, Jun J. Yang, Yen-Hsuan Ni, Ching-Hon Pui, Sung-Liang Yu, Yung-Li Yang

Summary: This study analyzed data from two consecutive protocols to determine the clinical impact of minimal/measurable residual disease (MRD) and tumor genetic subtypes in newly diagnosed pediatric acute lymphoblastic leukemia (ALL) patients. The results showed that MRD-directed therapy improved outcomes for pediatric ALL, especially for standard-risk patients. This study provides important data to inform the design of future clinical trials in Taiwan.

CANCER (2023)

Add to Collection

Article Oncology

Clinical application of next-generation sequencing-based monitoring of minimal residual disease in childhood acute lymphoblastic leukemia

Huirong Mai, Qin Li, Guobing Wang, Ying Wang, Shilin Liu, Xue Tang, Fen Chen, Guichi Zhou, Yi Liu, Tonghui Li, Lulu Wang, Chunyan Wang, Feiqiu Wen, Sixi Liu

Summary: This study explored the feasibility of using Next-generation sequencing (NGS) technology to detect minimal residual disease (MRD) in childhood acute lymphoblastic leukemia (ALL). The results showed that NGS is more sensitive than multiparametric flow cytometry (MFC) and real-time quantitative PCR (RQ-PCR) in detecting MRD. Furthermore, the number of clonal rearrangement sequences detected by NGS before treatment is an independent factor in predicting whether MRD can become negative after chemotherapy.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Hematopoietic stem cell transplantation for acute lymphoblastic leukemia: why do adolescents and young adults outcomes differ from those of children? A retrospective study on behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC)

Audrey Grain, Fanny Rialland-Battisti, Patrice Chevallier, Nicolas Blin, Jean-Hugues Dalle, Gerard Michel, Nathalie Dhedin, Regis Peffault de Latour, Cecile Pochon, Ibrahim Yakoub-Agha, Yves Bertrand, Anne Sirvent, Charlotte Jubert, Edouard Forcade, Ana Berceanu, Virginie Gandemer, Pascale Schneider, Jacques-Olivier Bay, Pierre-Simon Rohrlich, Eolia Brissot, Catherine Paillard, Dominique Plantaz, Stephanie Nguyen Quoc, Fanny Gonzales, Natacha Maillard, Lucie Planche, Andre Baruchel

Summary: This study compared the outcomes of children and young adults after hematopoietic stem cell transplantation (HSCT) for acute lymphoblastic leukemia (ALL). It found that young adults had lower overall survival and graft-versus-host disease (GvHD)-free survival rates, along with higher treatment-related mortality. The higher incidence of chronic GvHD appeared to be the primary factor contributing to the worse outcomes in young adults.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)

Add to Collection

Letter Oncology

Clonal evolution in hereditary thrombocytosis with MPL T487A mutation

Loic Vasseur, Remi Favier, Rathana Kim, Florence Rabian, Aurelie Cabannes-Hamy, Bruno Cassinat, Nabih Maslah, Nadia Vasquez, Emmanuelle Clappier, Jean-Jacques Kiladjian, Nicolas Boissel

PEDIATRIC BLOOD & CANCER (2023)

Add to Collection

Article Hematology

Allogeneic stem cell transplantation compared to conservative management in adults with inborn errors of immunity

Morgane Cheminant, Thomas A. Fox, Mickael Alligon, Olivier Bouaziz, Benedicte Neven, Despina Moshous, Stephane Blanche, Aurelien Guffroy, Claire Fieschi, Marion Malphettes, Nicolas Schleinitz, Antoinette Perlat, Jean-Francois Viallard, Nathalie Dhedin, Francoise Sarrot-Reynauld, Isabelle Durieu, Sebastien Humbert, Fanny Fouyssac, Vincent Barlogis, Benjamin Carpenter, Rachael Hough, Arian Laurence, Ambroise Marcais, Ronjon Chakraverty, Olivier Hermine, Alain Fischer, Siobhan O. Burns, Nizar Mahlaoui, Emma C. Morris, Felipe Suarez

Summary: Allogeneic hematopoietic stem cell transplantation (alloSCT) is a curative treatment for severe inborn errors of immunity (IEIs). Recent data suggests that alloSCT is safe and effective in selected adult patients. However, questions remain regarding the indications and optimal timing of the transplant.

BLOOD (2023)

Add to Collection

Article Biophysics

Combining blinatumomab and donor lymphocyte infusion in B-ALL patients relapsing after allogeneic hematopoietic cell transplantation: a study of the SFGM-TC

Paul Chauvet, Annalisa Paviglianiti, Myriam Labopin, Helene Labussiere, Nicolas Boissel, Marie Robin, Natacha Maillard, Marie Ouachee-Chardin, Edouard Forcade, Xavier Poire, Sylvain Chantepie, Anne Huynh, Claude Eric Bulabois, Mathieu Leclerc, Sebastien Maury, Patrice Chevallier, Thomas Cluzeau, Jean-Baptiste Mear, Jerome Cornillon, Karin Bilger, Celestine Simand, Yves Beguin, Marie-Therese Rubio, Ibrahim Yakoub-Agha, Eolia Brissot

Summary: This study compared the efficacy and safety of blinatumomab with donor lymphocyte infusion (DLI) versus blinatumomab alone in relapsed B-cell acute lymphoblastic leukemia (B-ALL) after allogeneic stem cell transplantation (allo-HCT). The results showed that adding DLI to blinatumomab treatment did not improve outcomes in B-ALL patients who relapsed after allo-HCT.

BONE MARROW TRANSPLANTATION (2023)

Add to Collection

Article Oncology

Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice: results from the NEUF study

Nicolas Boissel, Sabina Chiaretti, Cristina Papayannidis, Josep-Maria Ribera, Renato Bassan, Andrey N. Sokolov, Naufil Alam, Alessandra Brescianini, Isabella Pezzani, Georg Kreuzbauer, Gerhard Zugmaier, Robin Foa, Alessandro Rambaldi

Summary: This retrospective study included adult patients with B-cell ALL who were treated with blinatumomab for MRD+ or R/R B-cell ALL. The results showed significant treatment responses and survival benefits in both groups of patients.

BLOOD CANCER JOURNAL (2023)

Add to Collection

Article Hematology

Benefits of dexamethasone on early outcomes in patients with acute myeloid leukemia with hyperleukocytosis: a propensity score matched analysis

Marco Cerrano, Sylvie Chevret, Emmanuel Raffoux, Florence Rabian, Marie Sebert, Sandrine Valade, Raphael Itzykson, Virginie Lemiale, Lionel Ades, Nicolas Boissel, Herve Dombret, Elie Azoulay, Etienne Lengline

Summary: A study found that a short course of intravenous dexamethasone can reduce early mortality and improve overall survival in patients with hyperleukocytic acute myeloid leukemia (AML). The results of this study suggest that dexamethasone administration can be a promising strategy for treating high white blood cell AML.

ANNALS OF HEMATOLOGY (2023)

Add to Collection

Article Hematology

IL-7 receptor expression is frequent in T-cell acute lymphoblastic leukemia and predicts sensitivity to JAK inhibition

Lucien Courtois, Aurelie Cabannes-Hamy, Rathana Kim, Marine Delecourt, Antoine Pinton, Guillaume Charbonnier, Melanie Feroul, Charlotte Smith, Giulia Tueur, Cecile Pivert, Estelle Balducci, Mathieu Simonin, Laure Helene Angel, Salvatore Spicuglia, Nicolas Boissel, Guillaume P. Andrieu, Vahid Asnafi, Philippe Rousselot, Ludovic Lhermitte

Summary: T-cell acute lymphoblastic leukemia (T-ALL) is a hematological malignancy with a poor prognosis, and IL-7R expression can be used as a biomarker for predicting sensitivity to JAK inhibitors.

BLOOD (2023)

Add to Collection

Letter Hematology

IPSS-M in myelodysplastic neoplasms arising from aplastic anemia and paroxysmal nocturnal hemoglobinuria

Carmelo Gurnari, Pedro Henrique Prata, Luiz Fernando B. Catto, Arda Durmaz, Lise Larcher, Marie Sebert, Vincent Allain, Tariq Kewan, Simona Pagliuca, Andre L. Pinto, Mariana C. B. Inacio, Lucie Hernandez, Nathalie Dhedin, Sophie Caillat-Zucman, Emmanuelle Clappier, Flore Sicre de Fontbrune, Maria Teresa Voso, Valeria Visconte, Regis Peffault de Latour, Jean Soulier, Gerard Socie, Rodrigo T. Calado, Jaroslaw P. Maciejewski

BLOOD (2023)

Add to Collection

Article Hematology

Allogeneic transplantation in acute myelogenous leukemia: a comprehensive single institution's experience

Gerard Socie, Jacques-Emmanuel Galimard, Emmanuel Raffoux, Raphael Itzykson, Pierre Edouard Debureaux, David Michonneau, Etienne Lengline, Marie Robin, Flore Sicre de Fontbrune, Marie Sebert, Alienor Xhaard, Rathana Kim, Anne Couprie, Nathalie Dhedin, Matteo Dragani, Pierre Lemaire, Lise Larcher, Emmanuelle Clappier, Nicolas Boissel, Jean Soulier, Herve Dombret, Pierre Fenaux, Regis Peffault de latour, Lionel Ades

Summary: Debates on the role and timing of allogeneic hemtopoietic stem cell transplantation (HSCT) in acute myelogenous leukemia (AML) have persisted for decades. The current treatment algorithm mainly relies on the European LeukemiaNet disease risk classification. Our study analyzed all AML patients at diagnosis irrespective of age and comorbidities and estimated the cumulative incidence and potential benefit or disadvantage of HSCT.

HAEMATOLOGICA (2023)

Add to Collection

Letter Hematology

Real-world Experience of Approved Chimeric Antigen Receptor T-cell Therapies Compared to Clinical Trials Data

Jerome Lambert, Roberta Di Blasi, Florence Rabian, Marie-Emilie Dourthe, Andre Baruchel, Catherine Thieblemont, Nicolas Boissel, Vincent Levy, Marie-Quitterie Picat, Sylvie Chevret

HEMASPHERE (2023)

Add to Collection

Letter Hematology

Impact of T-cell Receptor Status on Mutational Landscape and Outcome in T-ALL

Marie Emilie Dourthe, Lucien Courtois, Guillaume P. Andrieu, Mathieu Simonin, Aurore Touzart, Ludovic Lhermitte, Arnaud Petit, Nicolas Boissel, Andre Baruchel, Vahid Asnafi, Elizabeth Macintyre

HEMASPHERE (2023)

Add to Collection

Article Oncology

Adult Low-Hypodiploid Acute Lymphoblastic Leukemia Emerges from Preleukemic TP53-Mutant Clonal Hematopoiesis

Rathana Kim, Hugo Bergugnat, Lise Larcher, Matthieu Duchmann, Marie Passet, Stephanie Gachet, Wendy Cuccuini, Marina Lafage-Pochitaloff, Cedric Pastoret, Nathalie Grardel, Vahid Asnafi, Beat W. Schaefer, Eric Delabesse, Raphael Itzykson, Lionel Ades, Yosr Hicheri, Yves Chalandon, Carlos Graux, Patrice Chevallier, Mathilde Hunault, Thibaut Leguay, Francoise Huguet, Veronique Lheritier, Herve Dombret, Jean Soulier, Philippe Rousselot, Nicolas Boissel, Emmanuelle Clappier

Summary: Low hypodiploidy is a common subtype of B-cell acute lymphoblastic leukemia (B-ALL) in older adults, characterized by somatic TP53 biallelic alteration. The study reveals a link between aging and low hypodiploidy ALL, with TP53-mutant clonal hematopoiesis serving as a preleukemic reservoir that can give rise to aneuploidy and B-ALL.

BLOOD CANCER DISCOVERY (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.